Abstract
Multisystem inflammatory syndrome in children (MIS-C) occurs during or recently following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is characterized by persistent fever, inflammation, and severe illness requiring hospitalization. The majority of patients with MIS-C also present with gastrointestinal (GI) symptoms, including abdominal pain, vomiting, and diarrhea. In this issue of the JCI, Yonker, Gilboa, and colleagues identified zonulin as a biomarker of GI permeability in children with MIS-C and present the results of an intriguing proof-of-concept study indicating that zonulin may represent a potential therapeutic target for MIS-C treatment and prevention. Their findings suggest that intestinal mucosal dysfunction and epithelial barrier breakdown may represent a biological mechanism underlying the development of MIS-C in SARS-CoV-2-infected children.
【초록키워드】 Treatment, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, Inflammation, coronavirus, Biomarker, Hospitalization, children, Infection, severe acute respiratory syndrome Coronavirus, abdominal pain, diarrhea, Symptoms, MIS-C, Fever, Patient, respiratory, epithelial, mechanism, persistent fever, mucosal, Inflammatory, dysfunction, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, syndrome, vomiting, potential therapeutic target, intestinal, characterized, majority, occur, children with MIS-C, 【제목키워드】 children, Inflammatory, syndrome,